J&J wants to be the leader in the cancer fight. Its strategy is starting to pay off as oncology sales top $25 billion in 2025.

by | Jan 21, 2026 | Stock Market

Johnson & Johnson sees revenue grow 9% in the fourth quarter, amid strength in its cancer drugs.

Article Attribution | Read More at Article Source